Version history

{
  "session_id": "sess_SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd_20260412-091505",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "critique",
  "content": "\n\n# Skeptic's Evaluation of Mechanistically-Specific Tau PTM Hypotheses\n\n---\n\n## Hypothesis 1: K280 Acetylation as Aggregation Nucleation Site\n\n### Strongest Specific Weakness\n\n**Mechanistic claim exceeds structural evidence.** The assertion that K280 acetylation creates a \"β-sheet nucleation interface\" implies a defined conformational change, yet no atomic-resolution structure of acetylated tau exists showing how this modification templated aggregation. The proposed mechanism conflates *correlation* (K280 acetylation correlates with disease) with *causation* (acetylation drives nucleation). Without a structural model of how the acetyl-lysine side chain at position 280 alters tau's prion-like propagation geometry, the \"nucleation interface\" remains a Black Box.\n\n### Counter-Evidence & Complications\n\n1. **Reversibility problem:** Acetyltransferases and deacetylases (especially SIRT1) dynamically regulate K280 acetylation. If acetylation truly creates a stable \"seeding template,\" how does the system maintain substrate specificity when deacetylation can reverse the modification within hours? The prion model requires templated propagation—acetylation's reversibility argues against stable conformational templating.\n\n2. **p300/CBP are pleiotropic with limited selectivity:** p300/CBP have ~2,000 known protein substrates (Wang et al., Nature 2013, PMID: 23927689). Pan-acetyltransferase inhibition would affect histone acetylation (gene regulation), metabolic enzymes, and cytoskeletal proteins. The therapeutic window for systemic p300/CBP inhibition is therefore narrow—this is not a selective tau-targeting approach.\n\n3. **K280 acetylation is not uniquely AD-specific:** Literature suggests K280 acetylation can occur in contexts beyond AD, including aging and other neurodegenerative conditions (Cohen et al. follow-up studies). If it's present in non-disease states, its specificity as a \"defining pathogenic event\" is weakened.\n\n4. **Phosphorylation remains dominant:** Tau's aggregation is most robustly seeded by phosphorylated tau (hyperphosphorylated at AT8 and AT100 epitopes). Acetylation may be a secondary modification that facilitates but doesn't define primary pathogenicity.\n\n### Pointed Question\n\n**Given that p300/CBP inhibition would affect thousands of substrates systemically, what evidence supports the claim that selective targeting of neuronal p300/CBP-mediated tau acetylation in the entorhinal cortex would achieve therapeutic benefit without disrupting critical hippocampal memory consolidation processes that also depend on histone acetylation?** Specifically, CBP is essential for consolidation of fear memory (Alarcón et al., 2002), and p300/CBP inhibitors have failed in cancer trials partly due to CNS side effects.\n\n### Confidence Rating: **MODERATE (overstated)**\n\nThe hypothesis has genuine mechanistic plausibility and solid foundational papers (Cohen, Cook). However, the disease-specificity claim is overstated given evidence of K280 acetylation in non-AD conditions, and the therapeutic targeting strategy via p300/CBP inhibition carries massive selectivity problems. The falsifiability criterion is met (the K280R prediction is testable), but the mechanistic framework linking acetylation to stable templated aggregation needs structural support.\n\n---\n\n## Hypothesis 2: Caspase-6 Cleavage at D421 (Truncated)\n\n*Note: The hypothesis text was incomplete. I'll evaluate based on the title and standard mechanistic framework for this modification.*\n\n### Strongest Specific Weakness\n\n**Caspase-6 activation may be a consequence, not a driver, of tau pathology.** The field has struggled to establish whether caspase-6 cleavage of tau is upstream or downstream of neurodegeneration. If tau aggregation itself triggers caspase-6 activation as a secondary event (e.g., through mitochondrial dysfunction and apoptosis signaling), then D421 cleavage is a *marker* of dying neurons, not a driver of spreading. Blocking caspase-6 cleavage would therefore not halt disease progression—it would merely prevent a downstream executional event.\n\n### Counter-Evidence & Complications\n\n1. **Caspase-6 is an executioner caspase—causality vs. executional role:** In classic apoptosis,",
  "tokens_used": "1054"
}